Efficient co-transduction of adenoviral vectors encoding carcinoembryonic antigen and survivin into dendritic cells by the CAR-TAT adaptor molecule enhance anti-tumor immunity in a murine colorectal cancer model
- PMID: 20211203
- DOI: 10.1016/j.imlet.2010.03.001
Efficient co-transduction of adenoviral vectors encoding carcinoembryonic antigen and survivin into dendritic cells by the CAR-TAT adaptor molecule enhance anti-tumor immunity in a murine colorectal cancer model
Abstract
Because multiple tumor antigens, including carcinoembryonic antigen (CEA) and survivin (SVV), have been frequently observed in human colorectal cancer, we investigated whether the expression of both CEA and SVV by co-transduction of adenovirus vectors into dendritic cells (DCs) could improve anti-tumor immunity in a murine colorectal cancer model. The adaptor fusion protein of Coxsackie and adenovirus receptor and TAT-protein transduction domain (CAR-TAT) enhanced co-transduction of adenovirus vectors encoding CEA (AdCEA) and SVV (AdSVV) into DCs, and increased anti-tumor immunity. DCs expressing both CEA and SVV in the presence of CAR-TAT (DC-AdCEA/AdSVV+CAR-TAT) induced T-cell responses specific for CEA and SVV, and enhanced cytotoxic T-cell activity on MC38/CEA2 cells expressing CEA and SVV compared with DCs expressing either CEA or SVV alone. Particularly, DC-AdCEA/AdSVV+CAR-TAT induced higher number of CEA-specific IFN-gamma secreting T cells compared with DC-AdCEA+CAR-TAT. Vaccination with DC-AdCEA/AdSVV+CAR-TAT also more efficiently inhibited tumor growth compared with DCs expressing either CEA or SVV alone in therapeutic tumor models. These results suggest that efficient co-transduction of multiple adenovirus vectors by CAR-TAT could be used to develop various strategies for therapeutic DC vaccines.
Copyright (c) 2010 Elsevier B.V. All rights reserved.
Similar articles
-
Dendritic cells transduced with recombinant adenoviruses induce more efficient anti-tumor immunity than dendritic cells pulsed with peptide.Vaccine. 2006 Apr 5;24(15):2860-8. doi: 10.1016/j.vaccine.2005.12.056. Epub 2006 Jan 13. Vaccine. 2006. PMID: 16443309
-
Efficient induction of anti-tumor immunity by a TAT-CEA fusion protein vaccine with poly(I:C) in a murine colorectal tumor model.Vaccine. 2011 Nov 3;29(47):8642-8. doi: 10.1016/j.vaccine.2011.09.052. Epub 2011 Sep 22. Vaccine. 2011. PMID: 21945963
-
Modification of CEA with both CRT and TAT PTD induces potent anti-tumor immune responses in RNA-pulsed DC vaccination.Vaccine. 2008 Nov 25;26(50):6433-40. doi: 10.1016/j.vaccine.2008.08.072. Epub 2008 Sep 21. Vaccine. 2008. PMID: 18812201
-
Novel recombinant alphaviral and adenoviral vectors for cancer immunotherapy.Semin Oncol. 2012 Jun;39(3):305-10. doi: 10.1053/j.seminoncol.2012.02.013. Semin Oncol. 2012. PMID: 22595053 Free PMC article. Review.
-
Analysis of survivin-specific T cells in breast cancer patients using human DCs engineered with survivin mRNA.Methods Mol Biol. 2013;969:275-92. doi: 10.1007/978-1-62703-260-5_17. Methods Mol Biol. 2013. PMID: 23296940 Review.
Cited by
-
Targeting cell death signaling in colorectal cancer: current strategies and future perspectives.World J Gastroenterol. 2014 Feb 28;20(8):1923-34. doi: 10.3748/wjg.v20.i8.1923. World J Gastroenterol. 2014. PMID: 24587670 Free PMC article. Review.
-
Lentiviral Vector Mediated Claudin1 Silencing Inhibits Epithelial to Mesenchymal Transition in Breast Cancer Cells.Viruses. 2015 Jun 10;7(6):2965-79. doi: 10.3390/v7062755. Viruses. 2015. PMID: 26067567 Free PMC article.
-
DNA and adenovirus tumor vaccine expressing truncated survivin generates specific immune responses and anti-tumor effects in a murine melanoma model.Cancer Immunol Immunother. 2012 Oct;61(10):1857-67. doi: 10.1007/s00262-012-1296-3. Epub 2012 Jun 17. Cancer Immunol Immunother. 2012. PMID: 22706381 Free PMC article.
-
Antitumor Vaccines Based on Dendritic Cells: From Experiments using Animal Tumor Models to Clinical Trials.Acta Naturae. 2017 Jul-Sep;9(3):27-38. Acta Naturae. 2017. PMID: 29104773 Free PMC article.
-
Combination of intensive chemotherapy and anticancer vaccines in the treatment of human malignancies: the hematological experience.J Biomed Biotechnol. 2010;2010:692097. doi: 10.1155/2010/692097. Epub 2010 Jun 2. J Biomed Biotechnol. 2010. PMID: 20625438 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical